
    
      The primary goal of this study is to identify the highest safe oral dose of MF101 that is
      well tolerated in humans.

      Secondary goals include: characterizing clinical symptoms of MF101 toxicity in healthy
      subjects and evaluating the dose-dependent pharmacokinetics of key MF101 active components
      after a single oral dose.
    
  